Transcatheter aortic valve implantation (TAVI) is an effective and less invasive treatment option compared with conventional surgical aortic valve replacement (SAVR), and is the standard of care for patients with severe aortic stenosis considered inoperable or at high surgical risk [1,2]. Currently, the indication for TAVI is shifting towards younger and lower risk patients [3–6]. Although TAVI techniques and the risk level of the treated population have improved over time, thromboembolic and bleeding complications are still frequent and negatively impact recovery and survival after TAVI.
